Trial Profile
A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 09 Jun 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2025.
- 25 Jun 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2021.
- 10 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Aug 2019, as reported by ClinicalTrials.gov.